CB-839, a glutaminase inhibitor, targets glutamine metabolism and has shown efficacy in preclinical studies across various cancers by depriving cells of a critical substrate needed for the TCA cycle and biosynthetic reactions [78]. The gene discussed is GLS; the disease is cancer.